Abstract
Despite the major improvement in therapeutic management of thalassemia major, iron overload is considered a challenging conundrum in these patients and heart disease still remains a major cause of morbidity and mortality in these patients. Therefore, this study aimed to investigate the prevalence of cardiac iron overload and cardiovascular complications in transfusion-dependent thalassemia patients in the worldwide. The following databases were searched: ISI/Web of Science, Embase, PubMed, Scopus, up to February 30, 2018. The quality of the studies was evaluated using the Joanna Briggs Institute Prevalence Critical Appraisal Tool. The random model based on Metaprop was used. One hundred forty-two studies were included. The total number of patients included was 26,893. The mean age of patients was 22.6 (SD = 1.7) years. Based on Metaprop, the overall prevalence of cardiac iron overload/myocardial sidoresis (T2* < 20 ms) and cardiac complications in thalassemia major patients in the worldwide was 25% (95% CI 22–28%) and 42% (95% CI 37–46%), respectively. The results of this study show that the prevalence of cardiac iron overload and cardiovascular complications in patients with thalassemia major is almost high. Therefore, iron chelation and careful monitoring of serum ferritin level will prevent the cardiac iron overload, and interval monitoring of patients with transfusion-dependent thalassemia (TDT) by echocardiography and electrocardiography will help with early detection of cardiovascular complications.
Similar content being viewed by others
Abbreviations
- β-TM :
-
β-Thalassemia major
- TDT :
-
Transfusion-dependent thalassemia
- CIO :
-
Cardiac iron overload
- PH :
-
Pulmonary hypertension
- TR :
-
Tricuspid regurgitation
- MRI :
-
Magnetic resonance
References
Higgs DR, Engel JD, Stamatoyannopoulos G (2012) Thalassaemia. Lancet 379:373–383
De Sanctis V, Kattamis C, Canatan D et al (2017) Beta-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterr J Hematol Infect Dis 9:e2017018
Williams TN, Weatherall DJ (2012) World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb Perspect Med 2:a011692
Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, Hoffman TM, Kiernan MS, Lerakis S, Piga A, Porter JB, Walker JM, Wood J (2013) Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 128:281–308
Krittayaphong R, Viprakasit V, Saiviroonporn P, Siritanaratkul N, Siripornpitak S, Meekaewkunchorn A, Kirawittaya T, Sripornsawan P, Jetsrisuparb A, Srinakarin J, Wong P, Phalakornkul N, Sinlapamongkolkul P, Wood J (2017) Prevalence and predictors of cardiac and liver iron overload in patients with thalassemia: a multicenter study based on real-world data. Blood Cell Mol Dis 66:24–30
Wijarnpreecha K, Kumfu S, Chattipakorn SC, Chattipakorn N (2015) Cardiomyopathy associated with iron overload: how does iron enter myocytes and what are the implications for pharmacological therapy? Hemoglobin 39:9–17
Bonifazi F, Conte R, Baiardi P, Bonifazi D, Felisi M, Giordano P, Giannuzzi V, Iacono A, Padula R, Pepe A, Caterina Putti M, Ruggieri L, Carlo del Vecchio G, Filosa A, Maggio A, Ceci A, HTA-THAL Multiregional Registry (2017) Pattern of complications and burden of disease in patients affected by beta thalassemia major. Curr Med Res Opin 33:1525–1533
Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, Keren A (2010) β-Thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail 3:451–458
Patel HV, Qari M, Mousa SA et al (2012) Iron balance in β-thalassemia: maintaining an antioxidant/oxidant ratio. J Appl Hematol 3:4
Carpenter J-P, Roughton M, Pennell DJ, Investigators MIiT (2013) International survey of T2* cardiovascular magnetic resonance in β-thalassemia major. Haematologica 98:1368–1374
Galanello R, Origa R (2010) Beta-thalassemia. Orphanet J Rare Dis 5:11
Russo V, Rago A, Papa AA, Nigro G (2016) Electrocardiographic presentation, cardiac arrhythmias, and their management in β-thalassemia major patients. Ann Noninvasive Electrocardiol 21:335–342
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
Munn Z, Moola S, Riitano D, Lisy K (2014) The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag 3:123–128
Nyaga VN, Arbyn M, Aerts M (2014) Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 72:39
Higgins J, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558
Deeks JJ, Higgins JP, Altman DG (2008) Analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions: Cochrane book series 26:243–296
Ades A, Lu G, Higgins J (2005) The interpretation of random-effects meta-analysis in decision models. Med Decis Mak 25:646–654
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj 315:629–634
Kremastinos D, Farmakis D, Aessopos A et al (2010) Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail 3:451–458
Yang G, Liu R, Peng P, Long L, Zhang X, Yang W, Tan S, Pan H, Long X, He T, Anderson L, Lai Y (2014) How early can myocardial iron overload occur in beta thalassemia major? PLoS One 9:e85379
Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, Thalassemia Clinical Research Network (2004) Complications of β-thalassemia major in North America. Blood 104:34–39
Richardson M, Matthews R, Alison J et al (1993) Prevention of heart disease by subcutaneous desferoxamine in patients with thalassaemia major. Intern Med J 23:656–661
Piga A, Gaglioti C, Fogliacco E, Tricta F (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88:489–496
Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M (2005) Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 127:1523–1530
Yaghobi M, Miri-Moghaddam E, Majid N et al (2017) Complications of transfusion-dependent β-thalassemia patients in Sistan and Baluchistan, south-east of Iran. Int J Hematol Oncol Stem Cell Res 11:268
Wood JC, Origa R, Agus A, Matta G, Coates TD, Galanello R (2008) Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica 93:917–920
Farhangi H, Badiei Z, Moghaddam HM, Keramati MR (2017) Assessment of heart and liver iron overload in thalassemia major patients using T2* magnetic resonance imaging. Indian J Hematol Blood Transfus 33:228–234
Aydinok Y, Porter JB, Piga A, Elalfy M, el-Beshlawy A, Kilinç Y, Viprakasit V, Yesilipek A, Habr D, Quebe-Fehling E, Pennell DJ (2015) Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. Eur J Haematol 95:244–253
Davis BA, O’Sullivan C, Jarritt PH, Porter JB (2004) Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 104:263–269
Wood JC (2009) Cardiac complications in thalassemia major. Hemoglobin 33:S81–S86
Srihirun S, Tanjararak N, Chuncharunee S, Sritara P, Kaewvichit R, Fucharoen S, Pattanapanyasat K, Sibmooh N (2015) Platelet hyperactivity in thalassemia patients with elevated tricuspid regurgitant velocity and the association with hemolysis. Thromb Res 135:121–126
Chate SC (2016) Cardiac abnormalities in patients with beta thalassemia. Int J Contemp Pediatr 3:224–228
Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennel DJ (2009) Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. J Cardiovasc Magn Reson 11:O2
Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, Fucharoen S, Cianciulli P, Grady RW, Prossomariti L, Porter JB, Iacono A, Cappellini MD, Bonifazi F, Cassarà F, Harmatz P, Wood J, Gluud C (2011) Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cell Mol Dis 47:166–175
Funding
This study is financially supported by the Research Deputy of Birjand University of Medical Sciences.
Author information
Authors and Affiliations
Contributions
F. Koohi was the main investigator and drafted the manuscript. E. Miri-Moghaddam and T. Kazemi were the study supervisors and contributed to all aspects of the study.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Koohi, F., Kazemi, T. & Miri-Moghaddam, E. Cardiac complications and iron overload in beta thalassemia major patients—a systematic review and meta-analysis. Ann Hematol 98, 1323–1331 (2019). https://doi.org/10.1007/s00277-019-03618-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-019-03618-w